Form 4 for NEPH NEPHROS INC
Accepted 2026-08-20 16:14:37 ET · period of report 2026-08-18 · accession 0001398344-26-015086 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-08-20 16:14 | 2026-08-18 | NEPH | WEXFORD CAPITAL LP | 10% | M - OptEx | $3.60 | +812 | 56.9K | +1% | +$2,923 |
| D | 2026-08-20 16:14 | 2026-08-18 | NEPH | WEXFORD CAPITAL LP | 10% | M - OptEx | $0.00 | -3,765 | 36.2K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-18 | M | A | 812 | $3.60 | 56,872 | D | — | — | (F1) Represents the net number of shares of common stock issued upon the cashless exercise of stock options to purchase 3,765 shares, after a portion of the option shares was withheld to satisfy the exercise price. (F2) Includes shares of common stock granted to Wexford Capital LP ("Wexford Capital") as reported in Form 4s previously filed by Arthur Amron, a current director of the Issuer and a former employee of Wexford Capital. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-08-18 | M | D | 3,765 | $0.00 | 36,198 | D | $3.60 · — to 2026-08-24 | 3,765 Common Stock | (F3) One-third of the options vested immediately upon the grant date of August 24, 2016. The remainder of the options vested in equal annual installments on each of the first and second anniversaries of the grant date. (F4) Includes stock options granted to Wexford Capital as reported in Form 4s previously filed by Arthur Amron, a current director of the Issuer and a former employee of Wexford Capital. |